VEGFA and neoplasm: Vascular endothelial growth factor inhibitors including bevacizumab have been shown to elicit a tumour antivascular response that is detectable by dynamic contrast-enhanced (DCE) MRI (O'Connor et al, 2009; Loveless et al, 2012).